Physician profile
Christopher Chong
NPI 1134564768
$4,067.68
in general payments reported to CMS, 2019-2025
22 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 95% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $13.76 · 2021: $80.03 · 2022: $434 · 2023: $856 · 2024: $343 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,055 · Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,054.64 |
| Food and Beverage | $1,317.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $2,322.79 | 2020-2025 | Iovera, Zilretta, Exparel |
| Zimmer Biomet Holdings, INC. | $282.59 | 2023-2025 | Gel-One Cross-Linked Hyaluronate |
| Abbott Laboratories | $280.56 | 2019-2023 | Freestyle Libre 3 |
| Depuy Synthes Sales INC. | $250.28 | 2023-2025 | Orthovisc, Monovisc, Peak |
| Ferring Pharmaceuticals INC. | $222.27 | 2021-2024 | Euflexxa |
| Novo Nordisk INC | $116.25 | 2022-2025 | |
| Lilly USA, LLC | $112.27 | 2022-2023 | Mounjaro, Jardiance |
| Bioventus LLC | $90.41 | 2022-2025 | Xcell, Durolane |
| Actelion Pharmaceuticals US, INC. | $55.91 | 2024 | Opsumit |
| Trice Medical, INC. | $46.39 | 2025 | |
| Almatica Pharma LLC | $38.59 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $38.08 | 2021-2023 | Austedo |
| Otsuka America Pharmaceutical, INC. | $31.77 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $29.08 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.89 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.71 | 2022 | |
| Hydrocision, INC. | $21.42 | 2024 | Tenjet |
| Exact Sciences Corporation | $18.95 | 2023 | Cologuard Collection Kit |
| Avanos Medical | $16.68 | 2019 | |
| Shire North American Group INC | $13.33 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.33 | 2022 | |
| Astellas Pharma US INC | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.